Sunday, March 15, 2020

Trump disbanded NSC pandemic unit that experts had praised



Trump disbanded NSC pandemic unit that experts had praised

By DEB RIECHMANNMarch 14, 2020

1 of 2

President Donald Trump takes questions during a news conference about the coronavirus in the Rose Garden of the White House, Friday, March 13, 2020, in Washington. Vice President Mike Pence, left, and Department of Health and Human Services Secretary Alex Azar, right listen. (AP Photo/Evan Vucci)

WASHINGTON (AP) — Public health and national security experts shake their heads when President Donald Trump says the coronavirus “came out of nowhere” and “blindsided the world.”

They’ve been warning about the next pandemic for years and criticized the Trump administration’s decision in 2018 to dismantle a National Security Council directorate at the White House charged with preparing for when, not if, another pandemic would hit the nation.

“It would be nice if the office was still there,” Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases at the National Institute of Health, told Congress this week. “I wouldn’t necessarily characterize it as a mistake (to eliminate the unit). I would say we worked very well with that office.”

The NSC directorate for global health and security and bio-defense survived the transition from President Barack Obama to Trump in 2017.

Trump’s elimination of the office suggested, along with his proposed budget cuts for the CDC, that he did not see the threat of pandemics in the same way that many experts in the field did.

One year later I was mystified when the White House dissolved the office, leaving the country less prepared for pandemics like COVID-19,” Beth Cameron, the first director of the unit, wrote in an op-ed Friday in The Washington Post.

She said the directorate was set up to be the “smoke alarm” and get ahead of emergencies and sound a warning at the earliest sign of fire — “all with the goal of avoiding a six-alarm fire.”

It’s impossible to assess the impact of the 2018 decision to disband the unit, she said. Cameron noted that biological experts remain at the White House, but she says it’s clear that eliminating the office contributed to what she called a “sluggish domestic response.” She said that shortly before Trump took office, the unit was watching a rising number of cases in China of a deadly strain of the flu and a yellow fever outbreak in Angola.

“It’s unclear whether the decision to disband the directorate, which was made in May 2018, after John Bolton became national security adviser, was a tactical move to downgrade the issue or whether it was part of the White House’s interest in simplifying and shrinking the National Security Council staff,” Cameron says.

The NSC during the Obama administration grew to about 250 professionals, according to Trump’s current national security adviser, Robert O’Brien. The staff has been cut to about 110 or 115 staffers, he said.

When Trump was asked on Friday whether closing the NSC global health unit slowed the U.S. response, the president called it a “nasty” question because his administration had acted quickly and saved lives.

“I don’t know anything about it,” Trump said.

Earlier, when asked about it, he said: “This is something that you can never really think is going to happen.”

On Saturday, John Bolton, a former Trump national security adviser, dismissed claims that “streamlining NSC structures impaired our nation’s bio defense are false.″ In a tweet, he said global health “remained a top NSC priority, and its expert team was critical to effectively handling the 2018-19 Africa Ebola crisis. The angry Left just can’t stop attacking, even in a crisis.″

For many years, the national intelligence director’s worldwide threat assessment has warned that a flu pandemic or other large-scale outbreak of a contagious disease could lead to massive rates of death and disability that would severely affect the world economy. Public health experts have been blowing whistles too.

Back in mid-2018, Fauci told Congress: “When you have a respiratory virus that can be spread by droplets and aerosol and ... there’s a degree of morbidity associated with that, you can have a catastrophe. ... The one that we always talk about is the 1918 pandemic, which killed between 50 and 100 million people. ... Influenza first, or something like influenza, is the one that keeps me up at night.”

The White House says the NSC remains involved in responding to the coronavirus pandemic.

A senior administration official said Friday that the NSC’s global health security directorate was absorbed into another division where similar responsibilities still exist, but under different titles. The work of coordinating policy and making sure that decisions made by Trump’s coronavirus task force are implemented is still the job of the NSC.

Some lawmakers aren’t convinced.

Rep. Gerald Connolly, D-Va., and Rep. Steve Chabot, R-Ohio, have introduced a bill that would require future administrations to have experts always in place to prepare for new pandemics.

“Two years ago, the administration dismantled the apparatus that had been put in place five years before in the face of the Ebola crisis,” Connolly said. “I think, in retrospect, that was an unwise move. This bill would restore that and institutionalize it.”

Connolly said the bill is not meant to be critical of the Trump administration. He said it’s a recognition that Trump had to name a coronavirus responder just like Obama had to name one for Ebola in 2014. “We can’t go from pandemic to pandemic,” Connolly said.

The House Foreign Affairs Committee on March 4 passed the measure, which is co-sponsored by 37 Democrats and five Republicans. The full House has not yet voted on the bill.

Chabot said one of the bill’s main goals is to would require personnel to be permanently in place preparing for pandemics.

“Specifically, we need someone, preferable at the NSC, to quarterback the U.S. government’s response since that response inevitably involves several agencies across the government,” Chabot said. “Our bill would make this position permanent.”

Former Obama administration officials insist that the Trump White House would have been able to act more quickly had the office still been intact.

“I think if we’d had a unit and dedicated professionals looking at this issue, gaming out scenarios well before ... we might have identified some of these testing issues,” says Lisa Monaco, President Obama’s homeland security adviser, said at a recent forum on coronavirus. “There would have been folks sounding the alarm in December when we saw this coming out of China, saying ’Hey, what do we need to be doing here in this country to address it?”

Ron Klain, who managed the government response to contain and mitigate the spread of Ebola in 2014, agreed.

“If I were back in my old job at the White House ... I’d be pushing to have us do 30 million tests — to test people in nursing homes, to test people with unexplained respiratory ailments, to test the people who regularly visit nursing homes, to test healthcare workers,” Klain said recently at the event hosted by the Center for American Progress in Washington.

Above is from:  https://apnews.com/ce014d94b64e98b7203b873e56f80e9a

Government official: Coronavirus vaccine trial starts Monday

Government official: Coronavirus vaccine trial starts MondayAP NEWS



By ZEKE MILLERan hour ago

A gun store customer that gave his name only at John waits in line, Sunday, March 15, 2020, in Burbank, Calif. As consumers are buying all kinds of goods in large quantities amid coronavirus concerns, putting pressure on inventories, John stated that he was there to buy ammunition because most other stores were out and he wanted to stock up. (AP Photo/Mark J. Terrill)

WASHINGTON (AP) — The first participant in a clinical trial for a vaccine to protect against the new coronavirus will receive an experimental dose on Monday, according to a government official.

The National Institutes of Health is funding the trial, which is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle. The official who disclosed plans for the first participant spoke on condition of anonymity because the move has not been publicly announced.

Public health officials say it will take a year to 18 months to fully validate any potential vaccine.

Testing will begin with 45 young, healthy volunteers with different doses of shots co-developed by NIH and Moderna Inc. There’s no chance participants could get infected from the shots, because they don’t contain the virus itself. The goal is purely to check that the vaccines show no worrisome side effects, setting the stage for larger tests.

Dozens of research groups around the world are racing to create a vaccine as COVID-19 cases continue to grow. Importantly, they’re pursuing different types of vaccines — shots developed from new technologies that not only are faster to produce than traditional inoculations but might prove more potent. Some researchers even aim for temporary vaccines, such as shots that might guard people’s health a month or two at a time while longer-lasting protection is developed.

Also in the works: Inovio Pharmaceuticals aims to begin safety tests of its vaccine candidate next month in a few dozen volunteers at the University of Pennsylvania and a testing center in Kansas City, Missouri, followed by a similar study in China and South Korea.

Even if initial safety tests go well, “you’re talking about a year to a year and a half” before any vaccine could be ready for widespread use, according to Dr. Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases.

That still would be a record-setting pace. But manufacturers know the wait — required because it takes additional studies of thousands of people to tell if a vaccine truly protects and does no harm — is hard for a frightened public.

President Donald Trump has been pushing for swift action on a vaccine, saying in recent days that the work is “moving along very quickly” and he hopes to see a vaccine “relatively soon.”

Today, there are no proven treatments. In China, scientists have been testing a combination of HIV drugs against the new coronavirus, as well as an experimental drug named remdesivir that was in development to fight Ebola. In the U.S., the University of Nebraska Medical Center also began testing remdesivir in some Americans who were found to have COVID-19 after being evacuated from a cruise ship in Japan.

For most people, the new coronavirus causes only mild or moderate symptoms, such as fever and cough. For some, especially older adults and people with existing health problems, it can cause more severe illness, including pneumonia. The worldwide outbreak has sickened more than 156,000 people and left more than 5,800 dead. The death toll in the United States is more than 50, while infections neared 3,000 across 49 states and the District of Columbia.

The vast majority of people recover. According to the World Health Organization, people with mild illness recover in about two weeks, while those with more severe illness may take three weeks to six weeks to recover.

___

The Associated Press receives support for health and science coverage from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Above is from:  https://apnews.com/8089a3d0ec8f9fde971bddd7b3aa2ba1